Study Type
Interventional - Drug
The objective of the DREAM study was to evaluate whether ramipril and/or rosiglitazone prevent the onset of type 2 diabetes in people with prediabetes and without cardiovascular disease.
The trial found no clear benefit for ramipril and a large reduction in incident diabetes with rosiglitazone. Ramipril did not reduce the incidence of CV and renal events; Rosiglitazone reduced the incidence of renal events, had an overall neutral effect on CV events and increased the incidence of heart failure. Based on the trial results rosiglitazone is suggested as a possible therapy to reduce the risk for diabetes in some countries.
Primary endpoint:
Composite newly diagnosed diabetes or death.
Secondary endpoints:
Composite of CV events
Myocardial infarction (MI)
Stroke
Congestive heart failure
Angina
Revascularization procedures
Ventricular arrhythmia
Renal events
All primary and secondary outcomes were adjudicated.
Interventional - Drug
Randomized, double-blind, placebo control, factorial assignment, efficacy study
21
191
5269
2002-2006
PHRI
Back To Top